Jolanda M. van Dieren

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Y.L. Verschoor, Joris van de Haar, José G. van den Berg et al. · Nature Medicine · 2024 · 93 citations · Full text

Contributions of mucosal immune cells to methotrexate-induced mucositis

Barbara AE de Koning, Jolanda M. van Dieren, Dicky J. Lindenbergh-Kortleve et al. · International Immunology · 2006 · 92 citations · Full text

Local application of tacrolimus in distal colitis: Feasible and safe

Jolanda M. van Dieren, Ad A. van Bodegraven, Ernst J. Kuipers et al. · Inflammatory Bowel Diseases · 2008 · 83 citations

A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015

Rosa T. van der Kaaij, Willem J. Koemans, Margreet van Putten et al. · European Journal of Cancer · 2020 · 65 citations

Population-based Study, Esophagus, Gastrointestinal Oncology +7

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Berend J. van der Wilk, Ben M. Eyck, Bas P. L. Wijnhoven et al. · The Lancet Oncology · 2025 · 61 citations · Full text

Surgical Oncology, Neoadjuvant Chemoradiotherapy, Esophageal Cancer +12